After his colon cancer returned in full force, Marine Corps veteran Joe Worthy decided to help other veterans, advocating for ...
CLEVELAND, Ohio — The benefits of getting regular exercise, combining two cancer drugs with chemotherapy, and using AI to ...
Preliminary results of fruquintinib in combination with FOLFIRI as second-line treatment for RAS-mutant metastatic colorectal cancer: A prospective, single-center phase 2 study. Efficacy and safety of ...
PDS01ADC is a tumor-targeted IL-12 immunocytokine designed to activate the immune system directly within the tumor ...
Stocktwits on MSN
PDSB stock hits 37-week high — here’s the latest on its therapy to treat metastatic colorectal cancer
The trial focused on patients with microsatellite-stable or mismatch repair-proficient metastatic colorectal cancer with liver metastases ・The treatment delivered an ORR of nearly 78%, compared to 35% ...
Objective Response Rate (ORR) with PDS01ADC; Parallel trial without PDS01ADC had 35% ORR 2-year survival rate of >80%; Parallel trial without PDS01ADC resulted in 2-year survival rate of ~35% Trials ...
September 27, 2012 — The US Food and Drug Administration (FDA) has approved the oral therapy regorafenib (Stivarga, Bayer) for the treatment of metastatic colorectal cancer. Regorafenib is a novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results